The effect of prolonged systemic doxycycline therapy on serum tissue degrading proteinases in coronary bypass patients: A randomized, double-masked, placebo-controlled clinical trial

Inflammation Research

Volumn 63, Issue 5, 2014, Pages 329-334

  Kormi, Immi ^a,b   Alfakry, Hatem ^b   Tervahartiala, Taina ^b   Pussinen, Pirkko J ^b   Sinisalo, Juha ^c   Sorsa, Timo ^b,c  

^a OULU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Atherosclerosis; Coronary bypass surgery; Doxycycline; Inflammation; Matrix metalloproteinases

Indexed keywords

C REACTIVE PROTEIN; DOXYCYCLINE; LEUKOCYTE ELASTASE; MATRILYSIN; MYELOPEROXIDASE; NEUTROPHIL COLLAGENASE; PLACEBO; TISSUE INHIBITOR OF METALLOPROTEINASE 1; ANTIINFECTIVE AGENT; MMP7 PROTEIN, HUMAN;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY BYPASS SURGERY; CORONARY RISK; DOUBLE BLIND PROCEDURE; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; HEART INFARCTION; HUMAN; IMMUNOFLUORESCENCE TEST; ISCHEMIC HEART DISEASE; LONG TERM CARE; MALE; NEPHELOMETRY; PROTEIN DEGRADATION; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; BLOOD; INFLAMMATION; MIDDLE AGED;

ANTI-BACTERIAL AGENTS; C-REACTIVE PROTEIN; CORONARY ARTERY BYPASS; DOUBLE-BLIND METHOD; DOXYCYCLINE; HUMANS; INFLAMMATION; MALE; MATRIX METALLOPROTEINASE 7; MATRIX METALLOPROTEINASE 8; MIDDLE AGED; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 84899650162     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-013-0704-2     Document Type: Article

References (40)

1. Sorsa T, Tjaderhane L, Konttinen YT, Lauhio A, Salo T, Lee HM, et al. Matrix metalloproteinases: contribution to pathogenesis, diagnosis and treatment of periodontal inflammation. Ann Med. 2006;38:306-21. (Pubitemid 44385100)
2. Tayebjee MH, Lip GY, MacFadyen RJ. Matrix metalloproteinases in coronary artery disease: clinical and therapeutic implications and pathological significance. Curr Med Chem. 2005;12:917-25. (Pubitemid 40443847)
3. Freestone T, Turner RJ, Coady A, Higman DJ, Greenhalgh RM, Powell JT. Inflammation and matrix metalloproteinases in the enlarging abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol. 1995;15:1145-51.
4. Galis ZS, Muszynski M, Sukhova GK, Simon-Morrissey E, Libby P. Enhanced expression of vascular matrix metalloproteinases induced in vitro by cytokines and in regions of human atherosclerotic lesions. Ann N Y Acad Sci. 1995;748:501-7.
5. Johnson JL. Matrix metalloproteinases: influence on smooth muscle cells and atherosclerotic plaque stability. Expert Rev Cardiovasc Ther. 2007;5:265-82. (Pubitemid 46488141)
6. Lambert E, Dassé E, Haye B, Petitfrère E. TIMPs as multifacial proteins. Crit Rev Oncol Hematol. 2004;49:187-98. (Pubitemid 38251351)
7. Visse Robert, Nagase Hideaki. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res. 2003;92:827-39.
8. Qiang H, Zhou ZX, Ma AQ, Cheng H, Zhou P. Implications of serum matrix metalloproteinase-8 elevation in patients with acute coronary syndrome. Nan Fang Yi Ke Da Xue Xue Bao. 2007;27:831-3.
9. Tuomainen AM, Nyyssonen K, Laukkanen JA, Tervahartiala T, Tuomainen TP, Salonen JT, et al. Serum matrix metalloproteinase-8 concentrations are associated with cardiovascular outcome in men. Arterioscler Thromb Vasc Biol. 2007;27:2722-8. (Pubitemid 350158928)
10. Herman MP, Sukhova GK, Libby P, Gerdes N, Tang N, Horton DB, et al. Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma: a novel collagenolytic pathway suggested by transcriptional profiling. Circulation. 2001;104:1899-904. (Pubitemid 32983231)
11. Turu MM, Krupinski J, Catena E, Rosell A, Montaner J, Rubio F, et al. Intraplaque MMP-8 levels are increased in asymptomatic patients with carotid plaque progression on ultrasound. Atherosclerosis. 2006;187:161-9. (Pubitemid 43817009)
12. Smith FB, Fowkes FG, Rumley A, Lee AJ, Lowe GD, Hau CM. Tissue plasminogen activator and leucocyte elastase as predictors of cardiovascular events in subjects with angina pectoris: Edinburgh artery study. Eur Heart J. 2000;21:1607-13.
13. Jones CB, Sane DC, Herrington DM. Matrix metalloproteinases: a review of their structure and role in acute coronary syndrome. Cardiovasc Res. 2003;59:812-23. (Pubitemid 38366237)
14. Halpert I, Sires UI, Roby JD, Potter-Perigo S, Wight TN, Shapiro SD. Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme. Proc Natl Acad Sci USA. 1996;93:9748-53. (Pubitemid 26296680)
15. Baldus S, Heeschen C, Meinertz T, Zeiher AM, Eiserich JP, Münzel T, et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation. 2003;108:1440-5. (Pubitemid 37176448)
16. Karakas M, Koenig W, Zierer A, Herder C, Rottbauer W, Baumert J. Myeloperoxidase is associated with incident coronary heart disease independently of traditional risk factors: results from the MONICA/KORA Augsburg study. J Intern Med. 2012;271:43-50.
17. Saari H, Suomalainen K, Lindy O, Konttinen YT, Sorsa T. Activation of latent human neutrophil collagenase by reactive oxygen species and serine proteases. Biochem Biophys Res Commun. 1990;171:979-87. (Pubitemid 20318046)
18. Wang Y, Rosen H, Madtes DK, Shao B, Martin TR, Heinecke JW, et al. Myeloperoxidase inactivates TIMP-1 by oxidizing its N-terminal cysteine residue: an oxidative mechanism for regulating proteolysis during inflammation. J Biol Chem. 2007;282:31826-34. (Pubitemid 350106428)
19. Fu X, Kassim SY, Parks WC, Heinecke JW. Hypochlorous acid generated by myeloperoxidase modifies adjacent tryptophan and glycine residues in the catalytic domain of matrixmetalloproteinase-7 (matrilysin): an oxidative mechanism for restraining proteolytic activity during inflammation. J Biol Chem. 2003;278:28403-9. (Pubitemid 36935741)
20. Kardara M, Papazafiropoulou A, Katsakiori P, Petropoulos C, Jelastopulu E. Protective effect of doxycycline use on coronary artery disease? J Infect. 2006;52:243-6.
21. Lauhio A, Konttinen YT, Tschesche H, Nordström D, Salo T, Lähdevirta J, et al. Reduction of matrix metalloproteinase-8-neutrophil collagenase levels during long term doxycycline treatment of reactive arthritis. Antimicrob Agents Chemother. 1994;38:400-2. (Pubitemid 24054275)
22. Golub LM, Lee HM, Ryan ME, Giannobile WV, Payne J, Sorsa T. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res. 1998;12:12-26.
23. Abdul-Hussien H, Hanemaaijer R, Verheijen JH, van Bockel JH, Geelkerken RH, Lindeman JH. Doxycycline therapy for abdominal aneurysm: improved proteolytic balance through reduced neutrophil content. J Vasc Surg. 2009;49:741-9.
24. Gu Y, Lee HM, Simon SR, Golub LM. Chemically modified tetracycline-3 (CMT-3): a novel inhibitor of the serine proteinase, elastase. Pharmacol Res. 2011;64:595-601.
25. Gu Y, Lee HM, Sorsa T, Salminen A, Ryan ME, Slepian MJ, et al. Non-antibacterial tetracyclines modulate mediators of periodontitis and atherosclerotic cardiovascular disease: a mechanistic link between local and systemic inflammation. Pharmacol Res. 2011;64:573-9.
26. Sinisalo J, Mattila K, Nieminen MS, Valtonen V, Syrjälä M, Sundberg S, Saikku P. The effect of prolonged doxycycline therapy on Chlamydia pneumoniae serological markers, coronary heart disease risk factors and forearm basal nitric oxide production. J Antimicrob Chemother. 1998;41:85-92. (Pubitemid 28064254)
27. Rautelin HI, Oksanen AM, Veijola LI, Sipponen P, Tervahartiala T, Sorsa T, et al. Enhanced systemic matrix metalloproteinase response in Helicobacter pylori gastritis. Ann Med. 2009;41:208-15.
28. Sorsa T, Tervahartiala T, Leppilahti J, Hernandez M, Gamonal J, Tuomainen AM, et al. Collagenase-2 (MMP-8) as a point-of-care biomarker in periodontitis and cardiovascular diseases. Therapeutic response to non-antimicrobial properties of tetracyclines. Pharmacol Res. 2011;63:108-13.
29. Dollery CM, Owen CA, Sukhova GK, Krettek A, Shapiro SD, Libby P. Neutrophil elastase in human atherosclerotic plaques: production by macrophages by macrophages. Circulation. 2003;107:2829-36. (Pubitemid 36705994)
30. Newby AC. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev. 2005;85:1-31. (Pubitemid 40171256)
31. Cheng C, Tempel D, van Haperen R, van Damme L, Algür M, Krams R, et al. Activation of MMP8 and MMP13 by angiotensin II correlates to severe intra-plaque hemorrhages and collagen breakdown in atherosclerotic lesions with a vulnerable phenotype. Atherosclerosis. 2009;204:26-33.
32. Hästbacka J, Tiainen M, Hynninen M, Kolho E, Tervahartiala T, Sorsa T, et al. Serum matrix metalloproteinases in patients resuscitated from cardiac arrest. The association with therapeutic hypothermia. Resuscitation. 2012;83:197-201.
33. van den Borne SW, Cleutjens JP, Hanemaaijer R, Creemers EE, Smits JF, Daemen MJ, et al. Increased matrix metalloproteinase-8 and -9 activity in patients with infarct rupture after myocardial infarction. Cardiovasc Pathol. 2009;18:37-43.
34. Kato R, Momiyama Y, Ohmori R, Taniguchi H, Nakamura H, Ohsuzu F. Plasma matrix metalloproteinase-8 concentrations are associated with the presence and severity of coronary artery disease. Circ J. 2005;69:1035-40. (Pubitemid 41603087)
35. Momiyama Y, Ohmori R, Tanaka N, Kato R, Taniguchi H, Adachi T, et al. High plasma levels of matrix metalloproteinase-8 in patients with unstable angina. Atherosclerosis. 2010;209:206-10.
36. Pussinen PJ, Sarna S, Puolakkainen M, Ohlin H, Sorsa T, Pesonen E. The balance of serum matrix metalloproteinase-8 and its tissue inhibitor in acute coronary syndrome and its recurrence. Int J Cardiol. 2012; doi:10.1016/j.ijcard. 2011.12.095.
37. Hanemaaijer R, Visser H, Koolwijk P, Sorsa T, Salo T, Golub LM, et al. Inhibition of MMP synthesis by doxycycline and chemically modified tetracyclines (CMTs) in human endothelial cells. Adv Dent Res. 1998;12:114-8.
38. García RA, Pantazatos DP, Gessner CR, Go KV, Woods VL Jr, Villarreal FJ. Molecular interactions between matrilysin and the matrix metalloproteinase inhibitor doxycycline investigated by deuterium exchange mass spectrometry. Mol Pharmacol. 2005;67:1128-36. (Pubitemid 40410413)
39. Tuomainen AM, Kormi I, Havulinna AS, Tervahartiala T, Salomaa V, Sorsa T, et al. Serum tissue-degrading proteinases and incident cardiovascular disease events. Eur J Prev Cardiol. 2012; doi:10.1177/2047487312465524.
40. Payne JB, Golub LM, Stoner JA, Lee HM, Reinhardt RA, Sorsa T, et al. The effect of subantimicrobial-dose-doxycycline periodontal therapy on serum biomarkers of systemic inflammation: a randomized, double-masked, placebo-controlled clinical trial. J Am Dent Assoc. 2011;142:262-73.